Allergic rhinitis (AR) is a common inflammatory disorder in the nasal mucosa caused by a hyperresponse of the immune system to allergens. The clinical symptoms of AR include sneezing, nasal discharge, itching, and congestion, which have a great impact on health-related quality of life. Since the 1960s, the global prevalence of AR has steadily increased. 1 Currently, the estimated prevalence of AR is 5%-15% in children and 10%-40% in adults. 2,3 The prevalence of allergen-specific immunoglobulin E (IgE) (to any allergen) has been estimated to exceed 50% of the population in Westernised countries. 1 Currently, pharmacotherapy is the cornerstone intervention for AR. However, while this method can control symptoms, it cannot reverse the state of immune imbalance of AR. Moreover, guidelinedirected pharmacotherapy is ineffective for up to 20% of people with AR. 4 Therefore, new and effective treatments are required.